Chimeric antigen receptor (CAR) T-cell therapy

In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]

In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]

With a median follow-up of 41.7 months, the overall response rate was 92% (95% CI, 85%–97%), and the complete response rate was 74%.

In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]

The 18-month PFS rate was 64.8% (95% CI, 54.2%–73.5%).[29][Level of evidence C2]

In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]

The median PFS was 40.2 months for patients with follicular lymphoma and was not reached for patients with marginal zone lymphoma.[30][Level of evidence C2]

In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]

Cytokine release syndrome occurred in 78% of patients and was grade 3 or 4 in 6% of patients.

In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]

Tocilizumab was required in 50% of all patients, and 5% required vasopressors. Grade 3 or 4 neurological events occurred in 15% of patients.

In a phase II trial, 98 patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy received anti-CD19 CAR T-cell therapy with tisa-cel.[31]

In a phase II trial, 98 patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy received anti-CD19 CAR T-cell therapy with tisa-cel.[31]

With a median follow-up of 16.6 months, the complete response rate was 69.1% (95% CI, 58.8%–78.3%), and the overall response rate was 86.2% (95% CI, 77.5%–92.4%).[31][Level of evidence C3]

In a phase II trial, 98 patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy received anti-CD19 CAR T-cell therapy with tisa-cel.[31]

Grade 3 or 4 cytokine release syndrome occurred in 48.5% of patients, and 37.1% had grade 3 or 4 neurotoxicity.

A phase II trial (NCT04245839) included 130 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy. Patients had high-risk features (progression of disease within 24 months after first-line chemoimmunotherapy or disease refractory to rituximab and alkylators). Patients received liso-cel.[32]

A phase II trial (NCT04245839) included 130 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy. Patients had high-risk features (progression of disease within 24 months after first-line chemoimmunotherapy or disease refractory to rituximab and alkylators). Patients received liso-cel.[32]

With a median follow-up of 18.9 months, the overall response rate was 97% (95% CI, 91.6%–99.4%), and the complete response rate was 94% (95% CI, 87.5%–97.8%).[32][Level of evidence C3]

A phase II trial (NCT04245839) included 130 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy. Patients had high-risk features (progression of disease within 24 months after first-line chemoimmunotherapy or disease refractory to rituximab and alkylators). Patients received liso-cel.[32]

Cytokine release syndrome occurred in 56% of patients and was grade 3 or higher in 1% of patients. Neurological side effects occurred in 15% of patients and was grade 3 or higher in 2% of patients.